Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
DETAILED ACTION
Status of the Claims
1. Claims 1-13 are the original claims filed 2/2/2024. In the preliminary response of 2/2/2024, claims 1-13 are canceled and new claims 14-26 are added. Claims 14-26 are all the claims.
2. The Examiner of the application has changed. This case has been transferred. To help in correlating any papers for this application, all further correspondence regarding this application should be directed to Lynn Bristol, Primary Examiner, Group Art Unit 1643.
Priority
3. USAN 1/8294,707 filed 02/02/2024 is a National Stage entry of PCT/EP2022/ 071961, International Filing Date: 08/04/2022, claims foreign priority to EP 21306087.4, filed 08/04/2021.
Election/Restrictions
4. Applicant’s election without traverse of Group II (Claims 22-26) in the reply filed on 8/17/2026 is acknowledged. Applicant’s election without traverse of species for VH (SEQ ID NO 18) and VL (SEQ ID NO: 20) in the reply filed on 8/17/2026 is acknowledged.
5. Claims 14-21 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 8/17/2026.
6. Claims 22-26 are all the claims under examination.
Information Disclosure Statement
7. As of 10/21/2026, two (2) IDS are filed: 2/2/2024; and 3/27/2024. The corresponding initialed and dated 1449 form is considered and of record.
8. The listing of references in the specification is not a proper information disclosure statement. 37 CFR 1.98(b) requires a list of all patents, publications, or other information submitted for consideration by the Office, and MPEP § 609.04(a) states, "the list may not be incorporated into the specification but must be submitted in a separate paper." Therefore, unless the references have been cited by the examiner on form PTO-892, they have not been considered.
Withdrawal of Rejections
Claim Rejections - 35 USC § 103
9. The rejection of Claim(s) 22-26 under 35 U.S.C. 103 as being unpatentable over Ghinea (WO 2018/172078; 9/27/2018; abstract) is withdrawn. Ghinea does not teach, suggest or contemplate the use of any FSHR blocking agent much less than an anti-FSHR antibody used in a method to treat atherosclerosis or arteriosclerosis in a patient.
Objections
Specification
10. The disclosure is objected to because of the following informalities:
a) The use of the term Alexa, RNeasy, Nanostring, Tris, LabChip, Nanodrop, which is a trade name or a mark used in commerce, has been noted in this application. The term should be accompanied by the generic terminology; furthermore the term should be capitalized wherever it appears or, where appropriate, include a proper symbol indicating use in commerce such as ™, SM , or ® following the term.
Although the use of trade names and marks used in commerce (i.e., trademarks, service marks, certification marks, and collective marks) are permissible in patent applications, the proprietary nature of the marks should be respected and every effort made to prevent their use in any manner which might adversely affect their validity as commercial marks.
b) The disclosure is objected to because it contains an embedded hyperlink and/or other form of browser-executable code. Applicants are required to delete the embedded hyperlink and/or other form of browser-executable code; references to websites should be limited to the top-level domain name without any prefix such as http:// or other browser-executable code. See MPEP § 608.01.
Appropriate correction is required.
Claim Objections
11. Claims 22-26 are objected to because of the following informalities:
a) Claims 22-26 are objected to because of ambiguity for an uncommon abbreviation that should be fully defined on the first occurrence in each claim, unless otherwise defined in a claim upon which the claim containing the abbreviation depends. Conversely, once an abbreviation has been identified, the abbreviation can be used after the first occurrence. Claim 22 should be amended to include the phrase “follicle-stimulating hormone receptor (FSHR)” in claim 22.
b) Claim 24 is objected to because abbreviations such as “FSH” should be fully defined on their first occurrence in each claim. Amend claim 24 to recite “follicle-stimulating hormone (FSH).”
c) Amend claim 24 to recite “FSH-induced signaling.”
Appropriate correction is required.
Claim Rejections - 35 USC § 112
The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.
Enablement (Prevention)
12. Claims 22-26 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.
Factors to be considered in determining whether undue experimentation is required, are summarized in In re Wands, 8 USPQ2d 1400 (Fed. Cir. 1988). They include the nature of the invention, the state of the prior art, the relative skill of those in the art, the amount of direction or guidance disclosed in the specification, the presence or absence of working examples, the predictability of the art, the breadth of the claims, the quantity of experimentation which would be required in order to practice the invention as claimed.
Claim interpretation
Claims 22-26 are drawn to a method of treating any atherosclerosis in any subject comprising administering any FSHR blocking agent.
“treatment’/ “treating”: the specification is unequivocal in teaching that both therapy and prophylaxis are encompassed within the meaning of the term at:
[0049] The terms “treating” or “treatment” refer to both therapeutic treatment and prophylactic or preventative measures; wherein the object is to prevent, reduce, alleviate, and/or slow down (lessen) one or more symptoms of atherosclerosis in a subject in need thereof. Symptoms of atherosclerosis include, without being limited to, chest pain or angina, shortness of breath, fatigue, confusion, limb pain, muscle weakness. In one embodiment, “treating” or “treatment” refers to a therapeutic treatment. In another embodiment, “treating” or “treatment” refers to a prophylactic or preventive treatment. In yet another embodiment, “treating” or “treatment” refers to both a prophylactic (or preventive) treatment and a therapeutic treatment. Those in need of treatment include those already with the disorder as well as those prone to have the disorder or those in whom the disorder is to be prevented. A subject or mammal is successfully “treated” for a disease or condition if, after receiving a therapeutic amount of a therapeutic agent, the patient shows observable and/or measurable reduction in or absence of one or more of the following: relief to some extent, of one or more of the symptoms associated with atherosclerosis; reduced morbidity and mortality, and improvement in quality-of-life issues. The above parameters for assessing successful treatment and improvement in the disease are readily measurable by routine procedures familiar to a physician.
Disclosure in the Specification
There is no evidence for in vivo prevention of atherosclerosis in a patient using just any FSHR blocking agent, much less any one of the claimed anti-FSHR antibodies.
Status of the Art
The nature of the invention is such that the FSHR blocking agent of the instant claims must be able to prevent atherosclerosis in a patient, much like a vaccine. The art teaches that a vaccine must be prophylactic (Stedman's Medical dictionary, 2000, lines 1-3). The specification does not provide any teachings of the prophylaxis of atherosclerosis, how to determine the individuals who will develop atherosclerosis, nor how to effectively prevent atherosclerosis before occurrence. Thus, one of skill in the art would not be able to use the FSHR blocking agent of the invention as a prophylactic without undertaking to determine how to select for subjects who will develop atherosclerosis before its occurrence in the subject. An effective protocol for the prevention of the formation of atherosclerosis is influenced by several factors, beyond the simple administration of the genus of just any FSHR blocking agent that blocks FSHR expression or intracellular signaling in atherosclerotic plaques (claim 23) much less prevents FSH induced signaling in atherosclerotic plaques (claim 24).
Whether a subject is at risk for developing atherosclerosis is an unpredictable proposition. Several factors play a role including but not limited to genetic makeup, environmental factors, smoking, high cholesterol levels, high blood sugar (glucose) levels, lack of exercise, poor dietary habits, and high blood pressure (see www.hopkinsmedicine.org/health/conditions-and-diseases/atherosclerosis).
The Patent Act requires that patent applicants describe the invention in explicit terms to enable any person skilled in the art to make and use the invention. 35 U.S.C. 112. Applicants seek an incalculable number of FSHR blocking agents know-and-yet-to-be discovered and that the specification does not teach how to make and use in the prevention of atherosclerosis. The enablement requirement is a crucial aspect of the patent “bargain”: an inventor is granted limited protection from competition in exchange for publicly disclosing their new technology. See the decision in Morse, Incandescent Lamp, and Holland Furniture, establishing the requirement that if a patent claims an entire class or genus of processes, machines, or compositions of matter, the specification must enable a person skilled in the field to make and use the entire class. If a patent claims an entire class of processes, machines, manufactures, or compositions of matter, the patent’s specification must enable a person skilled in the art to make and use the entire class. In other words, the specification must enable the full scope of the invention as defined by its claims. The more one claims, the more one must enable. See §112(a); see also Continental Paper Bag Co. v. Eastern Paper Bag Co., 210 U. S. 405 (1908) (“[T]he claims measure the invention.”).
Scope of Enablement (Therapy)
13. Claims 22-26 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for in vivo tissue staining with the claimed anti-FSHR antibodies, does not reasonably provide enablement for a therapeutic outcome in the treatment of a subject having atherosclerosis using the claimed anti-FSHR antibodies. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims.
Factors to be considered in determining whether undue experimentation is required, are summarized in In re Wands, 8 USPQ2d 1400 (Fed. Cir. 1988). They include the nature of the invention, the state of the prior art, the relative skill of those in the art, the amount of direction or guidance disclosed in the specification, the presence or absence of working examples, the predictability of the art, the breadth of the claims, the quantity of experimentation which would be required in order to practice the invention as claimed.
Claim interpretation
FSHR blocking agent: the agent is described in the specification at
[0033] The term “FSHR blocking agent” refers to any compound which inhibits or suppresses the expression or activity of the receptor. It is preferably an anti-FSHR antibody. In another particular embodiment, it can be a siRNA, or an antisense molecule. It may also be a chemical agent or a peptide. More preferably the FSHR ligand or blocking agent is a monoclonal antibody against FSHR.
The POSA could reasonably conclude the blocking agent is a genus of reach-through FSHR blocking agents that are not supported by the application by demonstration of their use in a method of treatment.
FSHR antibody: the specification does not define the genus, species and/or structure for the FSHR protein to which the antibodies of the invention bind. Wang at p. 9 (PTO 892) teaches the FSHR gene can produce various receptor subtypes through alternative splicing, among which the full-length FSHR1 and the truncated FSHR3 are representative. FSHR1 is a typical GPCR, primarily mediating the Gαs/cAMP/PKA pathway to regulate reproductive functions, while FSHR3 exhibits a structure more akin to growth factor receptors, with a signaling bias towards activating proliferation pathways such as MAPK.49 This fundamental difference in signaling output provides a crucial explanation for how FSH mediates different or even opposing biological effects in gonadal and extragonadal tissues. In gonadal tissues, it mainly regulates metabolism and differentiation through FSHR1; whereas in extragonadal sites such as vascular endothelium, adipose tissue, and liver, FSHR3 and other subtypes may dominate, directing FSH stimulation towards promoting inflammation, cell proliferation, and lipid synthesis, potentially leading to atherosclerosis.
The POSA could reasonably conclude that because the FSHR protein is ambiguous as regards the specificity for the binding of the instant claimed anti-FSHR antibodies, that the claimed method is not enabled for use in the method of treatment.
Disclosure in the Specification
The claims are not commensurate in scope with the enablement provided in the specification.
There is no evidence for in vivo therapeutic treatment of atherosclerosis in a patient using just any FSHR blocking agent, much less any one of the claimed anti-FSHR antibodies.
The experimentation while in vivo for binding of the antibodies to atherosclerotic plaques in mice, is not shown by intrinsic or extrinsic evidence to correlate with a therapeutic effect, in vivo.
There is no evidence for a genus of reach-through FSHR blocking agents, much less than being therapeutic in a patient.
The specification does not support or enable the broad scope of the claims which encompass any FSHR blocking agent because the specification does not disclose the following:
The specification provides insufficient guidance as to which of the essentially infinite possible of blocking agent is likely to be successful in a method of treatment, in vivo; and
The specification provides no guidance for the specificity of the anti-FSHR antibodies with respect to the genus, species and/or structure of the FSHR antigen to which they bind.
Thus, applicants have not provided sufficient guidance to enable one of ordinary skill in the art to make and use the claimed method invention in a manner reasonably correlated with the scope of the claims broadly including any number and kind of FSHR blocking agents. The scope of the claims must bear a reasonable correlation with the scope of enablement. See In re Fisher, 166 USPQ 19 24 (CCPA 1970). Without such guidance, the use of any FSHR blocking agent much less than the anti-FSHR antibodies, are untested in the extant application as-filed, and the experimentation left to those skilled in the art is unnecessarily and improperly extensive and undue. See Amgen, Inc. v. Chugai Pharmaceutical Co. Ltd., 927 F,2d 1200, 18 USPQ 1016 (Fed. Cir. 1991) at 18 USPQ 1026 1027 and Ex parte Forman, 230 USPQ 546 (BPAI 1986). "[T]o be enabling, the specification of a patent must teach those skilled in the art how to make and use the full scope of the claimed invention without undue experimentation.'" Genentech, Inc. v. Novo Nordisk, A/S, 108 F.3d 1361, 1365 (Fed. Cir. 1997) (quoting In re Wright, 999 F.2d 1557, 1561 (Fed. Cir. 1993)).
Unpredictability/ Undue Experimentation
The specification provides insufficient guidance as to which of the essentially infinite possible of blocking agent is likely to be successful in a method of treatment, in vivo; and
The specification provides no guidance for the specificity of the anti-FSHR antibodies with respect to the genus, species and/or structure of the FSHR antigen to which they bind.
Undue experimentation would be required to produce the invention commensurate with the scope of the claims from the written disclosure alone.
Furthermore, while the level of skill required to generate the antibodies is that of a molecular immunologist, the artisan of ordinary skill in the art would have been required to characterize the antibodies for the required functional attributes as claimed in claims 22-24, measure binding characteristics (e.g., binding specificity, equilibrium dissociation constant (KD), dissociation and association rates (K off and Kon respectively), and binding affinity and/or avidity compared with the parent antibody), and then finally perform bioassays to identify any one or more of the characteristics of any FSHR blocking agent known-and-yet to be discovered. The technology to perform these experiments was available at the time of application filing, but the amount of experimentation required to generate even a full working example of the instant claimed method would not have been routine much less could one of ordinary skill in the art predict that anyone generic FSHR blocking agent retained the antigen binding activity. (MPEP 2164.06, “The test is not merely quantitative, since a considerable amount of experimentation is permissible, if it is merely routine, or if the specification in question provides a reasonable amount of guidance with respect to the direction in which the experimentation should proceed.” (In re Wands, 858 F.2d 731, 737, 8 USQP2d 1400, 1404 (Fed. Cir. 1988) (citing In re Angstadt, 537 F.2d 489, 502-04, 190 USPQ 214, 217-19 (CCPA 1976)).
Conclusion
14. No claims are allowed.
15. Any inquiry concerning this communication or earlier communications from the examiner should be directed to LYNN A. BRISTOL whose telephone number is (571)272-6883. The examiner can normally be reached Mon-Fri 9 AM-5 PM.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Wu Julie can be reached at 571-272-5205. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/LYNN A BRISTOL/Primary Examiner, Art Unit 1643